Author

G. Lyons

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. A. Molinolo· 1 shared A. B. Sharabi· 1 shared A. Khanna· 1 shared D. Martin· 1 shared E. B. Roarty· 1 shared E. E. W. Cohen· 1 shared F. Sloulidis· 1 shared J. L. Callejas-Valera· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Molinolo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4

Z. Wang, V. H. Wu, M. M. Allevato, M. Gilardi, Y. He, J. L. Callejas-Valera, L. Vitale-Cross, D. Martin, P. Amornphimoltham, J. Mcdermott, Y. Goto, A. A. Molinolo, A. B. Sharabi, E. E. W. Cohen, Q. Chen, , J. S. Gutkind

This paper develops a syngeneic mouse model of tobacco-associated HNSCC that shows high response rates to anti-CTLA-4 therapy.

bioRxiv · Jun 15, 2019 · PreprintCancer Biology

Simplified Molecular Classification of Lung Adenocarcinomas Based on EGFR, KRAS, and TP53 Mutations

R. Ruiz-Cordero, J. Ma, A. Khanna, G. Lyons, W. Rinsurongkawong, R. Bassett, M. Guo, M. J. Routbort, J. Zhang, F. Sloulidis, J. V. Heymach, E. B. Roarty, Z. Tang, L. J. Medeiros, K. P. Patel, , S. Roy-Chowdhuri

This paper classifies lung adenocarcinomas into six subtypes based on EGFR, KRAS, and TP53 mutations, finding associations with prognosis and validating the classification against clinical outcomes.

bioRxiv · Jan 21, 2019Cancer Biology